obsolete_meningioma: ['A tumor of meningothelial cells that are manifested in the central nervous system and arise from the arachnoid "cap" cells of the arachnoid villi in the meninges.']
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
557 |
4. Check minimum number of eventsNone |
557 |
5. Include endpointsNone |
557 |
6. Filter based on genotype QC (FinnGen only) |
557 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D32
- Name in latin
- Neoplasma benignum meningum non specificatarum
Similar endpoints
↥List of similar endpoints to
Beningn neoplasm: Meninges, unspecified
based on the number of shared cases.
Similar with more cases:
- Beningn neoplasm: Meninges, unspecified
- Benign neoplasm of meninges
- Benign neoplasm of meninges
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4723 | 3470 | 1207 |
| Only index persons | 3764 | 2825 | 939 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.08 | 0.10 | 0.03 |
| Only index persons | 0.09 | 0.10 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 67.64 | 68.49 | 64.97 |
| Only index persons | 65.31 | 65.95 | 63.39 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 557 | 403 | 154 |
| Unadjusted period prevalence (%) | 0.12 | 0.14 | 0.07 |
| Median age at first event (years) | 63.12 | 61.55 | 67.23 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 513
- Matched controls
- 5129
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D32.9
ICD-10 Finland
Benign neoplasm: Meninges, unspecified
+∞
323.0
510
*
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
223.9
267.5
258
23
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
143.5
203.2
207
24
D32.02
ICD-10 Finland
Benign tumor of the meninges at the base of the brain
186.0
155.5
156
12
9530/0-C70.0
ICD-O-3
Meningioma, NOS, of cerebral meninges
160.9
146.4
149
13
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
20.0
129.3
208
169
D32.0
ICD-10 Finland
Benign neoplasm: Cerebral meninges
148.2
73.1
76
6
D32.01
ICD-10 Finland
Benign tumor of meninges on interhemispheric surface
112.9
72.2
77
8
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
89.7
57.4
63
8
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
13.3
56.5
103
95
N03AX14
ATC
levetiracetam; systemic
20.6
46.5
70
39
AA1AD
NOMESCO Finland
CT of head and brain
4.1
42.6
221
807
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
24.0
39.3
56
26
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
14.4
37.8
65
51
H02AB02
ATC
dexamethasone; systemic
5.1
37.6
133
327
G40.9
ICD-10 Finland
Epilepsy, unspecified
12.2
33.0
61
56
N03AB02
ATC
phenytoin; systemic
32.5
32.2
42
14
D32.03
ICD-10 Finland
Benign meningioma in ventricles
+∞
31.6
30
*
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
20.9
31.1
46
24
D32.07
ICD-10 Finland
Secondary or multiple benign tumor of the meninges below the exam
170.2
31.0
32
*
XCK00
NOMESCO Finland
Perimetry
5.8
30.5
93
189
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.5
29.7
95
204
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
17.9
29.5
46
28
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
18.8
29.4
45
26
9530/0-C70.9
ICD-O-3
Meningioma, NOS, of meninges, NOS
158.9
29.0
30
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.7
28.4
143
480
N03AF02
ATC
oxcarbazepine; oral
12.8
27.8
50
43
D32.1
ICD-10 Finland
Benign neoplasm: Spinal meninges
56.7
27.5
32
6
D32.06
ICD-10 Finland
Benign tumor of the meninges os petrosum or clivus area
73.7
25.0
28
*
N03AF01
ATC
carbamazepine; oral, rectal
6.0
24.0
69
129
D32.04
ICD-10 Finland
Secondary or multiple benign tumor of the meninges above the exam
131.1
23.8
25
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.2
22.1
133
500
D32.05
ICD-10 Finland
Cerebral meninges
65.5
22.0
25
*
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
11.3
21.8
41
39
ZXC95
NOMESCO Finland
Use of surgical navigator
16.7
20.9
33
21
N03AG01
ATC
valproic acid; systemic, rectal
5.5
19.1
58
116
9531/0-C70.0
ICD-O-3
Meningothelial meningioma of cerebral meninges
+∞
16.8
16
*
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
28.6
16.6
22
8
R51.80
ICD-10 Finland
Headache
3.0
16.6
106
409
XA800
NOMESCO Finland
Neuropsychological investigation
6.3
16.1
43
73
D43.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, supratentorial
34.6
15.8
20
6
AA1AG
NOMESCO Finland
Short MRI examination of brain with median intensity magnet
13.5
15.8
27
21
AA1BD
NOMESCO Finland
Extensive CT of head and brain
7.5
15.3
36
51
WX408
NOMESCO Finland
General anesthesy, balanced
2.3
15.0
166
870
H53.4
ICD-10 Finland
Visual field defects
9.1
14.9
31
36
R56.8
ICD-10 Finland
Other and unspecified convulsions
5.6
14.9
44
85
CS424
NOMESCO Finland
Visual field testing with Goldmann perimetry
14.7
14.7
24
17
2252A
ICD-9 Finland
Benign neoplasm of brain and other parts of nervous system, Cerebral meninges
82.5
14.6
16
*
D32
ICD-10 Finland
Benign neoplasm of meninges
82.5
14.6
16
*
9532/0-C70.0
ICD-O-3
Fibrous meningioma of cerebral meninges
+∞
13.6
13
*
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
5.6
13.5
39
74
G40.19
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
41.2
13.2
16
*
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
19.7
13.0
19
10
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
23.2
13.0
18
8
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.3
12.8
67
224
ZXC40
NOMESCO Finland
Use of ultrasound
18.6
12.1
18
10
N75
ICPC
Benign neoplasm nervous system
66.5
11.7
13
*
9539/1-C70.0
ICD-O-3
Atypical meningioma of cerebral meninges
122.6
11.5
12
*
G40.10
ICD-10 Finland
Simple partial seizures
15.5
11.4
18
12
ABB00
NOMESCO Finland
Excision of lesion of spinal canal
25.7
11.2
15
6
WX882
NOMESCO Finland
High dependency care
6.2
11.0
29
49
D43.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Central nervous system, unspecified
44.3
11.0
13
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
2.8
10.7
72
283
XCW99
NOMESCO Finland
Other investigative procedure of eye
2.6
10.6
79
330
9537/0-C70.0
ICD-O-3
Transitional meningioma of cerebral meninges
112.2
10.5
11
*
9530/0-C70.1
ICD-O-3
Meningioma, NOS, of spinal meninges
112.2
10.5
11
*
H47.2
ICD-10 Finland
Optic atrophy
23.9
10.3
14
6
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
11.6
10.1
18
16
AAK00
NOMESCO Finland
Cranioplasty
40.9
10.0
12
*
YX8BD
NOMESCO Finland
Stereotactic extensive CT examination for dose design of radiotherapy
20.5
9.8
14
7
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
15.4
9.6
15
10
G40.2
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
17.9
9.4
14
8
22520
ICD-8 Finland
Benign neoplasm of brain and other parts of nervous system, Cerebral meninges
101.8
9.4
10
*
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
22.2
9.4
13
6
G50.0
ICD-10 Finland
Trigeminal neuralgia
8.9
9.4
19
22
ZX050
NOMESCO Finland
Stereotactic radiotherapy
11.7
9.1
16
14
H53.2
ICD-10 Finland
Diplopia
5.0
9.0
28
59
YX8VG
NOMESCO Finland
Stereotactic MRI exmaination with high intensity magnet for dose design of radiotherapy
24.5
8.9
12
5
N76
ICPC
Neoplasm nervous system unspecified
91.5
8.4
9
*
8000/0-C70.0
ICD-O-3
Neoplasm, benign of cerebral meninges
91.5
8.4
9
*
N03AX18
ATC
lacosamide; systemic
14.8
8.2
13
9
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.1
8.2
46
160
D33.00
ICD-10 Finland
Medial pilosytic astrocytoma of the cerebrum
33.9
8.1
10
*
2152
FHL
Extraction, big brain
22.4
8.0
11
5
N06AB04
ATC
citalopram; systemic
1.9
7.9
124
724
183
Kela drug reimbursment
Lamotrigin and topiramate
11.0
7.8
14
13
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
9.6
7.8
15
16
N18
ICPC
Paralysis/weakness
6.5
7.8
19
30
D33.9
ICD-10 Finland
Benign neoplasm: Central nervous system, unspecified
45.7
7.7
9
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.0
7.4
97
529
D43.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, unspecified
81.2
7.4
8
*
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
1.8
7.2
127
775
H02AB09
ATC
hydrocortisone; systemic
5.8
7.1
19
34
N05BA01
ATC
diazepam; systemic, rectal
2.1
7.0
82
424
G44.2
ICD-10 Finland
Tension-type headache
2.2
7.0
74
368
D33.30
ICD-10 Finland
Acoustic neuroma
17.0
6.8
10
6
WX110
NOMESCO Finland
Local anesthesy
1.6
6.7
318
2562
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
12.5
6.6
11
9
N03AX09
ATC
lamotrigine; oral
3.6
6.5
27
77
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
2.2
6.4
63
302
WX404
NOMESCO Finland
Intravenous generell anesthesy
1.8
6.3
113
689
D33.08
ICD-10 Finland
Another benign tumor of the cerebral ventricle
+∞
6.3
6
*
N28
ICPC
Limited function/disability (N)
7.2
6.3
14
20
H05.2
ICD-10 Finland
Exophthalmic conditions
27.0
6.2
8
*
G91.0
ICD-10 Finland
Communicating hydrocephalus
12.7
6.1
10
8
S06.5
ICD-10 Finland
Traumatic subdural haemorrhage
4.1
6.1
22
56
WZC10
NOMESCO Finland
Extensive specialist consultion with written report
3.2
6.1
29
93
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.0
6.0
81
444
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
46
34
14.66
49.91
1.5
2.2
—
—
—
0
0
229
1451
1.98
13.36
2.7
2.1
172.2
230.5
u/l
0.49
221
1364
334
2408
1.97
13.29
6.8
6.0
1.2
1.2
mmol/l
0.96
297
2045
25
47
5.52
12.88
2.4
1.2
—
—
—
0
0
358
2675
1.95
12.44
5.6
4.3
6.7
6.7
mmol/l
0.02
344
2493
105
520
2.26
11.60
5.3
6.5
1.2
1.4
mmol/l
0.40
77
420
17
24
7.27
11.47
2.5
1.3
—
—
—
0
0
36
103
3.67
11.05
2.0
1.3
1153.3
199.9
e6/l
0.79
31
81
36
103
3.67
11.05
1.9
1.2
10.9
14.0
e6/l
0.14
29
78
86
407
2.32
10.52
2.5
1.9
373.1
378.5
nmol/l
0.07
80
374
171
1073
1.86
9.65
2.3
2.2
—
—
—
0
0
36
115
3.28
9.36
1.6
1.2
1058.8
475.1
mg/l
1.70
36
108
287
2207
1.62
7.19
6.2
5.2
1.2
1.2
mmol/l
3.00
269
1980
271
2070
1.60
6.88
4.3
4.0
—
—
—
0
0
247
1859
1.59
6.59
4.7
3.9
47.8
54.1
ng/l
0.09
191
1350
41
181
2.37
5.87
1.7
1.9
—
—
—
0
0
39
169
2.41
5.82
1.6
1.8
—
—
—
0
0
112
720
1.70
5.48
2.7
2.9
0.8
0.8
mmol/l
0.55
101
661
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
32
131
2.53
5.39
2.2
2.4
0.3
0.3
u/ml
0.04
17
75
301
2444
1.50
5.28
5.8
5.6
10.8
11.0
umol/l
0.09
285
2302
314
2578
1.50
5.17
9.3
8.4
4.1
4.1
e9/l
0.10
282
2248
113
744
1.65
5.03
1.9
1.8
—
—
—
0
0
51
263
2.03
5.01
3.7
2.9
4.0
4.5
pmol/l
3.35
46
221
191
1436
1.50
4.74
2.6
2.3
78.3
56.8
u/l
0.42
176
1313
49
262
1.95
4.37
1.6
1.7
—
—
—
0
0
69
413
1.77
4.34
2.4
2.6
4.5
6.1
ug/l
0.58
55
357
26
120
2.22
3.44
1.8
1.4
—
—
—
0
0
61
380
1.68
3.35
5.2
5.5
7.4
9.7
mmol/l
2.81
55
357
49
288
1.77
3.30
6.6
7.1
0.7
0.7
%
0.25
49
283
164
1270
1.41
3.30
3.4
3.1
0.4
0.4
e6/l
0.05
130
954
49
289
1.76
3.27
6.6
7.0
1.4
1.3
%
0.10
49
284
60
375
1.67
3.26
2.3
3.2
172.4
219.2
ng/l
0.36
52
347
89
617
1.53
3.15
20.3
24.2
1.5
1.2
inr
1.27
16
81
122
902
1.45
3.15
4.6
3.8
314.5
279.7
ng/l
0.05
92
716
47
278
1.75
3.11
1.2
1.4
—
—
—
0
0
204
1666
1.35
2.91
3.4
3.2
—
—
—
0
0
84
587
1.51
2.86
4.5
4.5
1.0
1.0
mmol/l
1.07
74
529
394
3582
1.34
2.55
8.4
7.0
76.5
78.3
u/l
0.42
371
3325
17
76
2.28
2.46
5.4
3.6
1.1
1.0
%
0.05
11
61
231
1960
1.31
2.43
2.1
2.0
97.7
97.0
pmol/l
0.08
108
962
378
3426
1.32
2.43
5.0
4.2
12.9
13.3
mm/h
0.23
355
3133
12
47
2.59
2.28
2.0
2.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
25
3.23
2.10
1.1
1.2
—
—
—
0
0
8
25
3.23
2.10
1.3
1.1
—
—
—
0
0
388
3565
1.29
2.05
5.1
4.1
14.8
14.9
pmol/l
0.53
364
3201
122
971
1.33
1.99
1.7
1.7
936.8
1203.4
nmol/l
3.03
91
711
94
726
1.35
1.87
2.9
2.9
2.3
2.9
e6/l
0.41
54
391
236
2061
1.25
1.84
4.6
4.1
34.8
35.3
g/l
0.65
216
1903
273
2424
1.25
1.84
3.0
2.7
—
—
—
0
0
177
1496
1.27
1.83
3.4
3.0
2026.0
1388.2
ng/l
0.67
152
1267
60
431
1.44
1.82
5.3
3.1
2.3
2.2
mmol/l
0.09
47
335
32
201
1.63
1.78
2.2
1.8
1.7
2.6
ug/l
0.21
27
178
29
178
1.66
1.76
3.9
3.5
1.0
1.3
mmol/l
2.50
29
172
99
782
1.32
1.71
2.9
2.7
1.4
1.2
e6/l
0.17
58
444
26
157
1.69
1.68
4.0
3.7
3.8
3.9
mmol/l
0.36
26
143
6
19
3.18
1.66
1.0
1.3
—
—
—
0
0
20
113
1.80
1.62
2.0
1.6
3.1
5.7
iu/l
—
9
30
19
106
1.82
1.60
4.3
2.2
3.3
3.9
g/l
1.11
19
101
11
50
2.22
1.58
1.1
1.1
—
—
—
0
0
226
1993
1.23
1.55
2.5
2.3
76.9
79.8
nmol/l
0.86
201
1746
69
526
1.36
1.51
1.9
1.8
—
—
—
0
0
6
21
2.88
1.51
1.2
1.1
—
—
—
0
0
49
354
1.42
1.48
1.3
1.6
—
—
—
0
0
68
522
1.34
1.43
1.8
1.7
—
—
—
0
0
24
149
1.64
1.43
1.2
1.2
—
—
—
0
0
9
40
2.27
1.40
1.0
1.1
—
—
—
0
0
127
1070
1.24
1.32
1.7
1.7
455.8
14220105.2
pmol/l
0.78
110
865
11
55
2.02
1.28
1.4
1.5
—
—
—
0
0
188
1655
1.21
1.27
3.3
3.2
2.4
2.4
mmol/l
0.59
165
1424
302
2777
1.19
1.26
3.2
3.0
47.7
48.4
u/l
0.05
274
2562
464
4446
1.26
1.25
21.1
14.5
22.8
22.7
mg/l
0.03
405
3529
8
36
2.24
1.24
1.4
1.3
—
—
—
0
0
16
93
1.74
1.22
1.1
2.2
117.5
129.7
g/l
—
8
64
64
501
1.31
1.21
2.8
2.3
5.2
7.4
umol/l
1.35
52
434
6
26
2.32
1.19
2.0
2.2
—
—
—
0
0
132
1136
1.21
1.12
2.4
2.1
2.9
3.2
mg/l
0.98
113
961
7
30
2.35
1.12
1.3
1.3
—
—
—
0
0
7
30
2.35
1.12
1.3
1.3
—
—
—
0
0
57
722
0.77
1.12
1.4
1.4
—
—
—
0
0
61
480
1.30
1.12
3.5
3.4
—
—
—
0
0
208
1872
1.18
1.08
3.0
2.6
108.3
118.0
ug/l
0.35
187
1707
7
33
2.14
1.06
1.3
1.2
—
—
—
0
0
23
154
1.51
1.05
3.4
2.0
—
—
—
0
0
35
256
1.39
1.03
3.7
2.8
0.1
0.2
e6/l
0.69
35
249
437
4187
1.20
1.02
18.7
13.7
77.4
76.4
ml/min/173m2
0.46
394
3414
437
4188
1.20
1.01
6.3
5.0
1.8
2.2
mu/l
0.87
408
3787
9
48
1.89
1.01
1.1
1.1
—
—
—
0
0
73
598
1.25
0.99
5.2
4.6
33.7
33.0
%
0.23
54
385
36
267
1.37
0.99
2.0
3.8
2.6
2.0
mmol/l
0.37
26
211
5
23
2.18
0.98
2.6
2.8
425.8
754.3
u/ml
—
5
23
50
392
1.30
0.96
3.1
3.4
1.2
1.2
mmol/l
0.43
50
336
9
51
1.78
0.95
1.3
1.7
—
—
—
0
0
38
287
1.35
0.94
2.1
3.8
5.2
5.2
kpa
0.03
33
269
21
143
1.49
0.91
1.5
1.6
0.0
0.5
iu/ml
—
7
28
10
56
1.80
0.88
1.8
1.4
—
—
—
0
0
345
3627
0.87
0.83
26.0
17.7
13.8
13.8
%
0.03
340
3551
35
267
1.33
0.83
1.1
1.4
—
31.6
—
0
14
6
33
1.83
0.79
1.2
1.2
—
—
—
0
0
19
132
1.45
0.77
1.1
1.2
—
—
—
0
0
114
1004
1.17
0.76
2.2
1.6
1.2
1.2
mg/l
0.12
87
784
6
34
1.77
0.76
1.2
2.8
—
—
—
0
0
6
34
1.77
0.76
7.7
3.3
—
—
—
0
0
9
54
1.68
0.75
1.3
1.6
—
—
—
0
0
5
26
1.93
0.71
1.0
1.0
—
—
—
0
0
7
41
1.72
0.70
1.1
1.2
—
81.8
—
0
6
478
4658
1.18
0.70
24.5
17.1
4.0
4.0
mmol/l
0.71
471
4521
154
1397
1.14
0.70
3.2
2.9
26.7
30.8
u/l
2.39
146
1323
71
606
1.20
0.69
8.3
7.5
—
—
—
0
0
9
59
1.53
0.68
1.1
1.1
—
—
—
0
0
49
408
1.22
0.62
2.5
2.6
65.5
66.4
g/l
0.44
44
367
5
30
1.67
0.61
3.8
1.7
—
—
—
0
0
9
140
0.64
0.61
1.3
1.6
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
476
4650
1.16
0.60
24.6
17.0
139.6
139.7
mmol/l
0.40
469
4522
106
948
1.15
0.59
2.8
2.8
2.4
2.5
mmol/l
0.68
85
827
29
228
1.29
0.59
4.1
2.1
0.6
0.7
%
0.20
29
220
15
107
1.41
0.56
1.2
1.4
—
—
—
0
0
6
37
1.63
0.55
1.3
1.7
—
—
—
0
0
20
152
1.33
0.52
1.4
1.2
—
—
—
0
0
9
63
1.44
0.52
1.2
1.4
—
—
—
0
0
9
63
1.44
0.52
1.2
1.4
—
—
—
0
0
9
63
1.44
0.52
1.2
1.4
—
—
—
0
0
6
97
0.61
0.52
1.5
1.5
—
—
—
0
0
377
3893
0.90
0.52
22.1
15.7
38.1
39.2
%
1.08
243
2622
9
64
1.41
0.51
1.2
1.4
—
—
—
0
0
9
65
1.39
0.50
1.2
1.4
—
—
—
0
0
9
65
1.39
0.50
1.2
1.4
—
—
—
0
0
84
751
1.14
0.49
1.4
1.3
4.9
13.2
u/ml
1.10
27
291
99
896
1.13
0.48
5.7
4.9
3.1
2.8
ug/l
0.18
80
790
126
1158
1.11
0.47
1.5
1.5
20.2
21.6
nmol/l
0.52
112
967
10
68
1.48
0.47
2.3
1.5
—
—
—
0
0
10
68
1.48
0.47
1.2
1.1
—
—
—
0
0
11
152
0.72
0.44
1.2
1.4
—
—
—
0
0
5
32
1.57
0.42
1.2
1.1
—
—
—
0
0
8
59
1.36
0.41
1.0
1.0
—
—
—
0
0
0
17
0.00
0.40
0.0
1.5
—
—
—
0
0
72
647
1.13
0.40
2.6
2.2
2.4
2.4
g/l
0.00
63
596
478
4699
1.12
0.40
24.1
17.3
76.5
76.3
umol/l
0.05
478
4699
19
151
1.27
0.39
1.4
1.2
—
—
—
0
0
68
611
1.13
0.38
2.8
2.2
19.8
21.7
%
0.60
56
520
5
36
1.39
0.38
1.0
1.1
—
—
—
0
0
5
37
1.35
0.37
1.0
1.2
—
—
—
0
0
9
71
1.27
0.36
1.1
1.2
0.5
0.6
nmol/l
—
9
64
13
99
1.32
0.35
1.4
1.3
—
—
—
0
0
9
121
0.74
0.35
1.4
1.7
—
—
—
0
0
11
82
1.35
0.34
2.2
1.7
—
—
—
0
0
13
101
1.29
0.32
1.2
1.1
—
—
—
0
0
7
53
1.32
0.31
1.4
1.1
—
—
—
0
0
78
718
1.10
0.30
5.2
4.5
21.8
21.7
%
0.03
45
362
10
75
1.34
0.30
1.3
1.3
—
—
—
0
0
123
1157
1.08
0.30
2.8
2.6
331.8
8066.1
umol/l
5.49
105
981
7
55
1.28
0.30
1.9
3.9
—
—
—
0
0
23
194
1.19
0.30
1.6
1.8
7.9
7.6
g/l
0.37
16
144
23
194
1.19
0.30
1.6
1.8
—
—
—
0
0
23
194
1.19
0.30
1.6
1.8
3.3
3.7
g/l
1.13
16
138
11
141
0.78
0.29
1.4
1.4
—
—
—
0
0
13
103
1.27
0.28
2.1
1.3
—
—
—
0
0
12
94
1.28
0.28
1.2
1.1
—
—
—
0
0
11
85
1.30
0.28
1.9
1.5
—
—
—
0
0
38
427
0.88
0.28
1.9
2.0
0.2
0.2
g/l
0.13
33
402
16
132
1.22
0.26
2.0
1.4
—
—
—
0
0
18
151
1.20
0.25
1.3
3.5
—
2.2
—
0
15
14
114
1.23
0.25
1.6
1.7
—
—
—
0
0
91
968
0.93
0.24
1.3
1.2
1.6
1.8
u/ml
0.06
19
261
116
1222
0.94
0.24
1.6
1.6
1.3
1.3
mmol/l
0.12
104
1015
76
709
1.08
0.23
2.7
2.2
12.3
12.7
umol/l
0.19
66
645
5
38
1.32
0.23
1.0
1.1
—
—
—
0
0
5
38
1.32
0.23
1.0
1.1
—
—
—
0
0
5
39
1.28
0.23
1.0
1.1
—
—
—
0
0
5
39
1.28
0.23
1.0
1.1
—
—
—
0
0
5
39
1.28
0.23
1.0
1.1
—
—
—
0
0
5
41
1.22
0.22
1.8
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
27
303
0.89
0.21
1.6
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
84
792
1.07
0.20
1.4
1.3
64.2
37.8
iu/ml
0.39
30
262
42
385
1.10
0.19
3.6
2.7
71.7
62.2
ml/min/173m2
—
10
161
11
90
1.23
0.19
1.5
2.5
14.6
15.9
%
—
6
42
12
100
1.20
0.18
1.5
1.3
—
—
—
0
0
12
100
1.20
0.18
1.5
1.3
—
—
—
0
0
20
226
0.88
0.17
1.8
1.5
—
—
—
0
0
7
62
1.13
0.17
1.1
1.1
—
—
—
0
0
6
78
0.77
0.15
1.0
1.2
40.5
18.6
u/l
—
6
64
23
208
1.11
0.14
6.6
3.2
24.5
24.3
mmol/l
0.09
23
187
60
631
0.94
0.13
1.8
1.5
—
—
—
0
0
24
219
1.10
0.13
1.5
1.3
—
—
—
0
0
232
2276
1.03
0.12
5.3
4.0
0.0
0.0
estimate
0.00
49
427
23
251
0.91
0.12
1.7
1.6
—
—
—
0
0
182
1781
1.03
0.11
6.0
4.3
—
—
—
0
0
446
4493
0.96
0.11
5.4
5.2
2.7
2.7
mmol/l
0.00
415
4090
470
4728
0.96
0.10
13.2
10.5
26.0
24.4
u/l
0.51
455
4536
5
46
1.09
0.09
1.6
1.7
—
—
—
0
0
5
46
1.09
0.09
1.6
1.7
—
—
—
0
0
5
46
1.09
0.09
1.6
1.7
—
—
—
0
0
14
155
0.90
0.09
2.2
2.8
—
—
—
0
0
232
2287
1.02
0.09
8.0
5.5
0.0
0.0
estimate
0.00
48
416
6
55
1.09
0.09
1.0
1.2
—
—
—
0
0
104
1013
1.03
0.09
5.5
4.5
1.0
1.0
kg/l
0.25
26
135
441
4384
1.03
0.08
4.8
4.6
4.7
4.7
mmol/l
0.44
413
4012
12
108
1.11
0.07
2.1
1.6
—
—
—
0
0
128
1255
1.03
0.07
5.2
4.4
0.0
0.0
estimate
0.00
47
413
234
2313
1.02
0.07
5.4
4.1
0.0
0.0
estimate
0.80
46
405
423
4208
1.02
0.06
6.9
6.0
40.8
40.1
mmol/mol
0.65
391
3870
42
405
1.04
0.05
3.4
3.2
79.7
78.3
ng/l
0.03
37
359
49
505
0.97
0.05
2.8
4.0
12.5
16.4
ug/l
0.14
41
427
142
1439
0.98
0.05
3.7
3.9
4.4
6.8
mg/mmol
1.08
92
877
420
4215
0.99
0.03
4.3
4.1
1.3
1.3
mmol/l
0.04
387
3805
138
1395
0.99
0.03
2.9
3.1
7.1
6.8
mmol/l
0.28
116
1166
40
411
0.97
0.03
2.8
2.3
26.2
34.2
u/l
1.11
33
344
437
4358
1.01
0.02
4.8
4.5
1.5
1.5
mmol/l
0.58
405
3966
53
521
1.02
0.02
3.7
3.1
0.8
0.8
ug/l
0.31
38
358
12
114
1.05
0.00
2.1
1.6
—
—
—
0
0
11
112
0.98
0.00
2.5
2.3
10.3
64.4
ug/min
—
6
65
21
208
1.01
0.00
1.0
1.0
—
—
—
0
0
439
4392
1.00
0.00
5.2
4.8
5.9
6.0
mmol/l
0.34
405
3961
30
299
1.00
0.00
1.1
1.2
149.1
157.0
iu/ml
—
10
124
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
5
49
1.02
0.00
3.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
7.9
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
106.8
—
0
6
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
6
60
1.00
0.00
3.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
6
69
0.87
0.00
1.3
1.6
—
—
—
0
0
6
63
0.95
0.00
1.3
1.6
—
—
—
0
0
7
78
0.90
0.00
2.7
1.6
—
—
—
0
0
7
75
0.93
0.00
1.4
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
1.3
—
0
9
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_MENINGES_NOS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_MENINGES_NOS | 1.849 [1.64, 2.08] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.382 |
During the follow-up period (1.1.1998 — 31.12.2019), 1164 out of 2919 females with CD2_BENIGN_MENINGES_NOS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_MENINGES_NOS | 1.959 [1.64, 2.35] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.033 |
During the follow-up period (1.1.1998 — 31.12.2019), 447 out of 1022 males with CD2_BENIGN_MENINGES_NOS died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_MENINGES_NOS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.178% | 0.389% |
| 5 | 0.971% | 2.184% |
| 10 | 2.724% | 5.914% |
| 15 | 5.12% | 10.892% |
| 20 | 9.169% | 19.39% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_MENINGES_NOS – Beningn neoplasm: Meninges, unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data